Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma

Pediatric Blood and Cancer

Volumn 56, Issue 5, 2011, Pages 749-756

  Souza, Daniela Raguer Valadão de ^a   Sanabani, Sabri Saeed ^b   Souza, Ana Carolina Mamana Fernandes De ^a   Odone, Vicente Filho ^a   Epelman, Sidnei ^c   Bendit, Israel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FUNDAÇÃO PRÓ SANGUE HEMOCENTRO DE SÃO PAULO   (Brazil)

^c HOSPITAL SANTA MARCELINA   (Brazil)

Author keywords

Gene expression; Neuroblastoma; Risk classification

Indexed keywords

MESSENGER RNA;

ARTICLE; BRAIN BIOPSY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

CHILD; CHILD, PRESCHOOL; DEAD-BOX RNA HELICASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RECEPTOR, TRKA; RECEPTOR, TRKC; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79952179097     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22823     Document Type: Article

References (54)

1. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995; 31A: 505-510.
2. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874-1881.
3. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
4. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116.
5. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 581-591.
6. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86: 364-372.
7. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369: 2106-2120.
8. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-1124.
9. Schmidt ML, Salwen HR, Manohar CF, et al. The biological effects of antisense N-myc expression in human neuroblastoma. Cell Growth Differ 1994; 5: 171-178.
10. Negroni A, Scarpa S, Romeo A, et al. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 1991; 2: 511-518.
11. Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 2005; 23: 6474-6480.
12. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-854.
13. Nisen PD, Waber PG, Rich MA, et al. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988; 80: 1633-1637.
14. Seeger RC, Wada R, Brodeur GM, et al. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 1988; 271: 41-49.
15. Nakagawara A, Kadomatsu K, Sato S, et al. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res 1990; 50: 3043-3047.
16. Chan HS, Gallie BL, DeBoer G, et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997; 3: 1699-1706.
17. Cohn SL, London WB, Huang D, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000; 18: 3604-3613.
18. Alaminos M, Gerald WL, Cheung NK. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Pediatr Blood Cancer 2005; 45: 909-915.
19. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21: 181-189.
20. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 2000; 18: 1260-1268.
21. Nakagawara A. Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett 2001; 169: 107-114.
22. Tanaka T, Hiyama E, Sugimoto T, et al. trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study. Cancer 1995; 76: 1086-1095.
23. Ryden M, Sehgal R, Dominici C, et al. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 1996; 74: 773-779.
24. Nakagawara A, Azar CG, Scavarda NJ, et al. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759-767.
25. George RE, Kenyon R, McGuckin AG, et al. Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer 1997; 33: 2037-2042.
26. Squire JA, Thorner PS, Weitzman S, et al. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene 1995; 10: 1417-1422.
27. Kaneko S, Ohira M, Nakamura Y, et al. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. J Cancer Res Clin Oncol 2007; 133: 185-192.
28. Weber A, Imisch P, Bergmann E, et al. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 2004; 22: 2681-2690.
29. Souza AC, Souza DR, Sanabani SS, et al. The performance of semi-quantitative differential PCR is similar to that of real-time PCR for the detection of the MYCN gene in neuroblastomas. Braz J Med Biol Res 2009; 42: 791-795.
30. Coelho MC, Tannuri U, Benditt I, et al. Studies of RET gene expression and acetylcholinesterase activity in a series of sporadic Hirschsprung's disease. Pediatr Surg Int 2008; 24: 1017-1021.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
32. Alaminos M, Mora J, Cheung NK, et al. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res 2003; 63: 4538-4546.
33. Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004; 64: 6883-6891.
34. Ohira M, Oba S, Nakamura Y, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005; 7: 337-350.
35. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006; 24: 5070-5078.
36. Oberthuer A, Warnat P, Kahlert Y, et al. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Lett 2007; 250: 250-267.
37. Schramm A, Schulte JH, Klein-Hitpass L, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005; 24: 7902-7912.
38. Fredlund E, Ringner M, Maris JM, et al. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 2008; 105: 14094-14099.
39. Slavc I, Ellenbogen R, Jung WH, et al. myc gene amplification and expression in primary human neuroblastoma. Cancer Res 1990; 50: 1459-1463.
40. Peirce SK, Findley HW. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity. Oncol Rep 2009; 22: 1443-1449.
41. Fulda S, Lutz W, Schwab M, et al. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999; 18: 1479-1486.
42. Fulda S, Lutz W, Schwab M, et al. MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. Med Pediatr Oncol 2000; 35: 582-584.
43. Westermann F, Muth D, Benner A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008; 9: R150.
44. Oberthuer A, Theissen J, Westermann F, et al. Molecular characterization and classification of neuroblastoma. Future Oncol 2009; 5: 625-639.
45. Nakagawara A, Arima M, Azar CG, et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364-1368.
46. Suzuki T, Bogenmann E, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85: 377-384.
47. Manohar CF, Salwen HR, Brodeur GM, et al. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. Genes Chromosomes Cancer 1995; 14: 196-203.
48. De Preter K, Speleman F, Combaret V, et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 2002; 15: 159-166.
49. De Preter K, Speleman F, Combaret V, et al. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol 2005; 23: 3167-3168; author reply 3168-3170.
50. Aoki T, Ichimura S, Itoh A, et al. Identification of the neuroblastoma-amplified gene product as a component of the syntaxin 18 complex implicated in Golgi-to-endoplasmic reticulum retrograde transport. Mol Biol Cell 2009; 20: 2639-2649.
51. Lavenius E, Gestblom C, Johansson I, et al. Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor. Cell Growth Differ 1995; 6: 727-736.
52. Matsushima H, Bogenmann E. Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo. Mol Cell Biol 1993; 13: 7447-7456.
53. Lavoie JF, Lesauteur L, Kohn J, et al. TrkA induces apoptosis of neuroblastoma cells and does so via a p53-dependent mechanism. J Biol Chem 2005; 280: 29199-29207.
54. Tajiri T, Higashi M, Souzaki R, et al. Classification of neuroblastomas based on an analysis of the expression of genes related to prognosis. J Pediatr Surg 2007; 42: 2046-2049.